American Made Pharmaceuticals Act of 2024

This bill establishes a 7-year demonstration program testing preferential treatment for U.S.-manufactured drugs in Medicare, Medicaid, and CHIP programs. It directs the Secretary to implement the program in at least 8 states, using tools like formulary preference or lower patient cost-sharing for drugs made by qualifying U.S. pharmaceutical companies. To qualify, drugs must be manufactured in the U.S. by companies meeting specific transparency, supply chain diversity, and inventory standards, including critical drugs identified in executive orders or deemed high-risk for shortages. The program aims to assess how U.S. manufacturing preferences affect drug access and costs within federal health programs. The Secretary must submit annual reports to Congress on program results and recommendations.